FDA Approves Novo Nordisk’s Pasatru for FOP, Accelerates Approval for Tudriqev Combination in Melanoma, and Greenlights mFLUSIVA mRNA Flu Vaccine

August 23, 2026

Drugs.com USA

Overview

In August 2026, the FDA approved several key new drugs. Novo Nordisk’s Pasatru (garetosmab-grts) gained approval for adults with Fibrodysplasia Ossificans Progressiva (FOP). An accelerated approval was granted for the combination of Tudriqev (vusolimogene oderparepvec-wtpg) and nivolumab for unresectable advanced cutaneous melanoma, offering a new immunotherapeutic option. Furthermore, the mFLUSIVA mRNA influenza vaccine received approval for seasonal flu prevention, broadening the application of mRNA technology.

In Depth

Key Findings

In August 2026, the U.S. Food and Drug Administration (FDA) announced approvals for several significant new drugs and vaccines, encompassing rare disease therapeutics, innovative immunotherapies, and mRNA technology. Notably, Novo Nordisk’s Pasatru (garetosmab-grts) was approved for adults with Fibrodysplasia Ossificans Progressiva (FOP), while a combination of Tudriqev (vusolimogene oderparepvec-wtpg) and nivolumab received accelerated approval for unresectable advanced cutaneous melanoma. Additionally, the mFLUSIVA mRNA influenza vaccine was approved for the prevention of seasonal influenza.

Technical/Clinical Details

Pasatru (garetosmab-grts): Fibrodysplasia Ossificans Progressiva (FOP) is a rare, progressive genetic disorder where muscles and connective tissues gradually ossify, severely restricting mobility. The approval of Pasatru offers a groundbreaking therapeutic approach aimed at slowing the progression of FOP, addressing a high unmet medical need in this devastating condition. While specific mechanisms of action and detailed clinical trial data are pending further release, this approval marks a crucial step for FOP patients who previously had no approved treatment options.
Tudriqev (vusolimogene oderparepvec-wtpg) + Nivolumab Combination Therapy: This combination for unresectable advanced cutaneous melanoma pairs Tudriqev, a genetically modified herpes simplex virus-based oncolytic virus, with the immune checkpoint inhibitor nivolumab. The oncolytic virus selectively infects and lyses cancer cells, simultaneously stimulating an immune response that enhances the effects of nivolumab’s checkpoint blockade. This accelerated approval provides a powerful new treatment option for patients with advanced melanoma, promising improved response rates and delayed disease progression.
mFLUSIVA mRNA Influenza Vaccine: mFLUSIVA has been approved as an mRNA vaccine for the prevention of seasonal influenza. Leveraging the mRNA technology proven effective in COVID-19 vaccines, mFLUSIVA promises more rapid manufacturing capabilities and enhanced adaptability against circulating viral strains. This approval heralds a new era in influenza vaccine development and production, potentially offering superior protection and quicker responses to evolving threats.

Background & Context

These approvals reflect continuous progress across key innovation areas within the biopharmaceutical industry: rare diseases, cancer immunotherapy, and preventive medicine. The development of therapies for conditions like FOP is critical for patient populations with limited options, indicating advances in personalized medicine. New combination immunotherapies for melanoma signify ongoing efforts to overcome the recalcitrance of difficult-to-treat cancers, pushing beyond the limits of existing treatments. The application of mRNA technology to influenza vaccines demonstrates how lessons learned from pandemic responses are being effectively translated to address other significant public health challenges.

Strategic Significance & Outlook

The approvals of these new drugs and vaccines are poised to significantly impact their respective disease areas. FOP patients will gain access to a potential first-in-class therapy that could slow disease progression. Melanoma patients will benefit from a new, potent option that enhances existing immunotherapy, leading to potentially better outcomes. The mFLUSIVA mRNA influenza vaccine not only offers a new tool for seasonal prevention but also strengthens preparedness for future influenza pandemics, while accelerating the development of mRNA vaccines for other infectious diseases. These advancements collectively promise substantial improvements in patient quality of life and public health worldwide.

Source: https://www.drugs.com/newdrugs.html

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.